Product Description
Labeled iron salt. Fe salt enriched with Fe 58 isotopes (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02993835)
Mechanisms of Action: Radioactive Agent
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Nestle
Company Location: VEVEY V8
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| IPPERU | N/A |
Completed |
Anemia, Iron-Deficiency |
2019-08-08 |
|
| 18.05.INF | N/A |
Completed |
Inflammation |
2019-06-12 |
|
| SASHA-II | N/A |
Completed |
Anemia, Iron-Deficiency |
2019-05-03 |
|
| 16.15.NRC | N/A |
Completed |
Healthy Volunteers |
2017-02-01 |
|
| EK-2009-N-19 | N/A |
Completed |
Malaria, Falciparum|Ancylostomiasis|Hookworm Infections |
2013-09-01 |
|
| 10/12 Fonio Study Benin | N/A |
Completed |
Anemia, Iron-Deficiency |
2011-01-01 |